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Abstract  
Acute respiratory distress syndrome (ARDS) is the often fatal sequelae of a broad range of 
precipitating conditions. Despite decades of intensive research and clinical trials there remain 
no therapies in routine clinical practice that target the dysregulated and overwhelming 
inflammatory response that characterises ARDS. Neutrophils play a central role in the 
initiation, propagation and resolution of this complex inflammatory environment by 
migrating into the lung and executing a variety of pro-inflammatory functions. These include 
degranulation with liberation of bactericidal proteins, release of cytokines and reactive 
oxygen species as well as production of neutrophil extracellular traps. While these functions 
are advantageous in clearing bacterial infection, the consequence of associated tissue damage, 
the contribution to worsening acute inflammation and prolonged neutrophil lifespan at sites 
of inflammation are deleterious. In this review, the importance of the neutrophil will be 
considered along with discussion of recent advances in understanding neutrophil function and 
the factors that influence them throughout the phases of inflammation in ARDS. From better 
understanding of neutrophils in this context potential therapeutic targets are identified and 
discussed. 
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Introduction  
Acute respiratory distress syndrome (ARDS) is the often fatal final sequalae to a broad range 
of direct and indirect pulmonary insults that include both infective and sterile aetiologies such 
as pneumonia, aspiration of gastric contents, sepsis, acute hepatic failure and acute 
pancreatitis. ARDS is defined by an acute onset of respiratory symptoms; profound systemic 
hypoxaemia; diffuse, bilateral infiltrates on chest x-ray and the exclusion of cardiac failure or 
fluid overload as a precipitant [1]. Despite decades of intensive research, the mortality rate 
for ARDS remains approximately 40% with no effective pharmacological therapies in routine 
clinical practice [2]. The failure to translate a large number of promising therapeutic agents 
from pre-clinical studies is well described [3]. Challenges arise when attempting to develop 
drugs that span the diverse and heterogenous conditions that precipitate ARDS, the 
differences in the inflammatory phenotypes and underlying genomic variation within this 
patient population, as well as the difficulties in the translation of observations in animal 
models into human inflammatory disease [3]. Distinct from inter-individual variation is also 
the complexity of redundancy and dysregulation of the inflammatory environment that 
characterises ARDS. Despite these challenges the need to develop novel therapeutics is 
pressing. 
 
ARDS is characterised by an overwhelming, dysregulated and self-perpetuating pro-
inflammatory environment; there is a significant increase in a range of pro-inflammatory 
mediators accompanied by rapid recruitment of neutrophils into the alveolar space, 
endothelial injury and dysfunction, platelet aggregation and microthrombus formation, 
interstitial and alveolar oedema, alveolar epithelial cell death and macrophage activation [4]. 
Diffuse alveolar damage is the typical histological hallmark of this exudative phase, although 
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the histological appearances can be very variable between individuals who have died from 
severe ARDS [5]. Following alveolar damage, there is a proliferative phase with resolution of 
pulmonary oedema, type II alveolar cell hyperplasia, early collagen deposition and release of 
pro-resolving mediators including lipoxins and resolvins [6,7]. Whilst inflammation and 
injury completely resolves to leave no clinical, radiological or physiological impairment in 
some individuals, there remains a substantial cohort who subsequently develop diffuse 
pulmonary fibrosis and chronic lung disease [8]. 
 
Within this inflammatory milieu there are multiple cell types with direct roles in disease 
pathogenesis including macrophages, epithelial and endothelial cells. There is, however, an 
established body of literature that implicates the neutrophil as central to driving this 
inflammatory state [9,10]. Increased neutrophil numbers, the presence of neutrophil-derived 
proteases and the chemotactic factors that drive neutrophil recruitment are associated with 
increased disease severity and higher mortality rates [9,11]. Similarly, neutrophil depletion, 
inhibition of key chemokines and signalling molecules, or acceleration of apoptosis to 
shorten neutrophil lifespan, results in improvement in oxygenation, reduction in 
inflammation and accelerated inflammation resolution in pre-clinical models [12–15]. To 
date, however, clinical trials targeting neutrophil function in ARDS have failed to show 
benefit in overall survival [3,16]. 
 
While much has been written on the detailed mechanisms of neutrophil migration and 
function in inflammation [17–19] this review focuses on those observations that have been 
demonstrated within the context of ARDS and pre-clinical models of acute lung injury. In 
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doing so we hope to provide a focus on those pathological mechanisms that are of potential 
clinical relevance and may therefore represent therapeutic targets of the future (Table 1). 
 
Neutrophil recruitment and function 
The recruitment of neutrophils to the lung makes them a key factor in the pathogenesis of 
ARDS. In response to inflammatory mediators, either originating from the lung or distant 
organ injury, circulating neutrophils become primed and alter their cytoskeletal architecture 
with retention in the pulmonary capillary bed.  They then migrate out of postcapillary venules 
across the endothelium, through the interstitium and epithelium and into alveoli, with 
associated local tissue dysfunction and destruction due to release of histotoxic mediators such 
as neutrophil extracellular traps, reactive oxygen species and proteases (Figure 1). This 
induction of epithelial and endothelial injury contributes to the development of alveolar 
oedema and hypoxaemia as well as exacerbating the pro-inflammatory state. It should be 
recognised that neutrophil migration into the lung without concomitant activation does not 
induce tissue injury [13]. However, there are conflicting models with regards to the 
mechanisms by which initial neutrophil activation occurs. It has been proposed that activation 
of the intravascular immune system, through an increase in circulating proinflammatory 
mediators, results in neutrophil priming, adhesion and/or trapping in lung capillaries. 
Subsequent migration along a variety of chemotactic gradients into the lung parenchyma 
therefore results in secondary lung injury [20]. The alternative hypothesis is that release of 
pro-inflammatory mediators by alveolar macrophages plays a vital role in the initiation of 
inflammation [21], triggering an inflammatory cascade by activating surrounding tissues and 
resulting in chemotaxis of inflammatory cells such as neutrophils to the airways [21]. It is 
likely that the exact mode of initial neutrophil recruitment and activation varies depending on 
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the inciting stimulus and whether this is intrapulmonary or systemic. However, the end result 
in both cases is the recruitment of neutrophils to the lung resulting in tissue injury.  
 
PAMPs and DAMPs 
Both sterile and infective tissue injury result in neutrophil recruitment into the lung through 
complementary mechanisms. In the context of infection, pathogen-associated molecular 
patterns (PAMPs) including lipopolysaccharide (LPS), lipoteichoic acid, DNA, RNA and 
proteins such as formylated peptides are released and recognised by the immune system [22]. 
PAMPs can bind to, and are sensed by, a variety of pathogen recognition receptors (PRRs) 
including toll-like receptors (TLRs) and Nod-like receptors (NLRs) [23]. PRRs and their 
downstream signalling pathways drive chemotaxis as well as priming and activating both 
intravascular and transmigrated neutrophils in order to fulfil their bactericidal functions 
[22,24]. TLRs play an important role in regulating the response to pro-inflammatory 
mediators and are rapidly upregulated in mouse models of sepsis-related acute lung injury 
[25]. In early sepsis-related ARDS, downregulation of TLR1, TLR4 and TLR5 transcripts in 
mononuclear cells correlates with increased survival [23], while in a pulmonary contusion 
mouse model of lung injury, alveolar neutrophil recruitment is TLR4/MyD88 dependent [26]. 
Similarly, TLR4-deficiency is associated with a reduction in sterile pulmonary inflammation 
and more rapid resolution of injury through alterations in downstream synthesis of cysteinyl 
leukotrienes and subsequent induction of suppressor of cytokine signalling of cytokines 3 
(SOCS3) within the lung. In this context, a reduction in TLR4-mediated oxidative stress was 
observed but, surprisingly, alveolar neutrophil numbers were increased [27]. While this 
suggests an important role for TLRs in acute lung injury, the functional importance of 
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neutrophils in this model is limited, thereby serving to emphasise that understanding of 
neutrophil-mediated TLR function in ARDS requires further investigation. 
 
Sterile tissue injury, either in the context of direct injury to lung parenchyma or distant organ 
injury, results in necrotic cell death with the release of a range of damage-associated 
molecular patterns (DAMPs) into the extracellular environment. These DAMPs serve to 
induce a proinflammatory response which drives neutrophil recruitment into the lung [25,27]. 
A number of DAMPs have been described in ARDS including high mobility group box 1 
(HMGB1), heat shock proteins 60 and 72, hyaluronan and a range of mitochondrial-derived 
factors including DNA, formylated peptides and cardiolipin [28]. Due to common 
evolutionary ancestry and relative structural and sequence homology with bacteria it appears 
these mitochondrial factors play an important role in driving the development of neutrophil-
mediated lung injury. Mitochondrial DNA is elevated in patients with ARDS and, through 
interaction with endosomal TLR9, mediates neutrophil recruitment [29]. Importantly, it is 
also been shown to be a predictive biomarker of mortality in patients in intensive care, 
including those with ARDS, and therefore further studies with regards to both its role as a 
clinically significant predictive biomarker in ARDS and as a therapeutic target are needed. 
 
Mitochondrial formylated peptides play a crucial role in neutrophil recruitment in ARDS as 
well as altering epithelial and endothelial cell function [29–31]. Elevated levels of these 
peptides are found in bronchoalveolar lavage fluid and serum of ARDS patients [31]. The 
importance of formyl peptide receptor 1 (FPR1, the cognate receptor for formylated peptides) 
in influencing acute inflammation is well established [32]. Genetic deletion of Fpr1 in mice 
is associated with reduced survival in infection but an attenuated inflammatory response in 
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the context of sterile tissue injury [29,31,33]. FPR1, a G-protein coupled receptor, activates a 
variety of intracellular signalling pathways including PI3K, mitogen-activated protein kinases 
(MAPKs) and Akt pathways [34]. This serves to directly alter neutrophil migration, reactive 
oxygen species production, degranulation and transcriptional activity [32]. In sterile lung 
injury in mice, neutrophil chemotaxis, along with other indices of pulmonary inflammation, 
were diminished in Fpr1
-/-
 mice or in the presence of an FPR1 antagonist delivered either 
prior to, or following, acid-induced lung injury. This suggests that FPR1 may represent a 
therapeutic target in sterile ARDS but, as with many other therapies targeting neutrophil 
function, addressing the challenge of concurrent infection needs to be addressed [31].  
 
Chemokines and Cytokines 
Chemokines, a family of chemotactic cytokines, play a crucial role in neutrophil migration to 
sites of inflammation [35]. CXC chemokines, in particular CXCL8 (IL-8), play an important 
role in neutrophil chemotaxis in ARDS with elevated levels associated with poor disease 
prognosis, increased severity and mortality [36–38]. Produced by local immune cells and 
epithelial cells, CXCL8 is not the only chemokine responsible for the recruitment of 
neutrophils to the lung, as blockade results in only partial reduction in alveolar neutrophil 
number [13,35]. CCL2 and CCL7 are also elevated in the BALF of both LPS-challenged 
volunteers and ARDS patients and neutralising either chemokine reduces neutrophil 
chemotactic responses in vitro [39]. Interestingly, CCL2 and CCL7 also potentiate the 
activity of CXCL8, suggesting synergistic activity between these chemokines drives 
neutrophil recruitment in ARDS. The CXCL8 receptor, CXCR1, is more highly expressed on 
circulating neutrophils from ARDS patients relative to the CCL2/7 receptors CCR1, CCR2 
and CCR3 [39]. However, a significant increase in neutrophil CCR2 expression in BALF 
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fluids has been observed, with the authors postulating that this confers an increased 
sensitivity to cognate ligands CCL2 and CCL7 in the alveolar space and therefore suggesting 
an important role in neutrophil chemotaxis within the lung. Other chemokines including 
CXCL5, and mediators such as C5a and leukotriene B4 (LTB4), have also been shown to have 
a role in driving neutrophil chemotaxis in ARDS [40].   
 
While the majority of cytokines are produced by other cell types, neutrophils also secrete a 
range of cytokines that potentiate the inflammatory response. These include TNF, which has 
been associated with microvascular plasma protein leakage [41], and IL-1β, which potentiates 
the pro-inflammatory cycle by inducing further cytokine and chemokine release and thereby 
recruiting more neutrophils to the lung [42]. Furthermore, antibody-mediated inhibition of the 
TNF receptor (TNFR1) reduced alveolar neutrophil recruitment, inflammatory cytokine 
release and biomarkers of endothelial injury in BALF and serum samples in experimental 
acute lung injury. As a result, inhibiting TNFR1 could be considered as a potential option in 
the treatment of ARDS [43]. 
 
After a non-pulmonary acute injury such as traumatic brain injury, burn injury or sepsis, 
mediators including IL-1β, IL-6, CXCL8, IL-18 and TNF as well as a variety of DAMPs are 
released into the systemic circulation [23,36,44–47]. For example, intravascular neutrophil 
priming and activation, as part of a systemic inflammatory response syndrome that occurs 
following traumatic brain injury, results in neutrophil migration into the lung [47] and other 
organs including the liver and kidney [48,49], inducing tissue injury and dysfunction. 
Similarly, the pro-inflammatory cytokines TNF and IL-1β were found to be elevated in the 
BALF of ARDS patients
 
alongside the natural antagonists IL-1RA and soluble TNF receptors 
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[50]. It appears, however, that an imbalance between agonists and antagonists exists which 
drives the acute phase inflammatory response [51]. 
 
At present, there have been no specific clinical trials investigating the pharmacological 
manipulation of the majority of chemokines, although steroids effecting their function 
through suppression of chemokine/cytokine axis has been proposed. Current clinical trial data 
on the use of steroids in ARDS is mixed and there is no definitive evidence for improved 
survival, and in some cases has been found to worsen outcome. While improved effects on 
ventilator-free days has been described, an increase in return to mechanical ventilation is 
increased amongst those receiving steroids, as are significant side effects including 
neuromyopathy and hyperglycaemia) [52–55]. 
 
Selectins and Integrins 
In order for neutrophils to enter the alveolar space, selectins play an important role in 
initiating the process of neutrophil tethering and rolling along the endothelial surface. L-
selectin, one such adhesion molecule present on neutrophils, has been found (in its soluble 
form) to be reduced in the plasma of ARDS patients, which directly correlated to ventilation 
requirements, degree of respiratory failure and mortality [57,58]. Conversely, elevated 
plasma levels of E-selectin and P-selectin, expressed by endothelial cells, correlated with 
increased mortality [58–60]. Most recently, through genome wide association studies, three 
nonsynonymous single nucleotide polymorphism (SNPs) in the Selectin P Ligand Gene 
(SELPLG) have been identified to be associated with sepsis-related ARDS [61]. PSGL1 (the 
encoded protein) acts as an important ligand for both L-selectin and P-selectin. In LPS-
induced lung injury, inflammation is attenuated in Selplg
-/-
 mice while an inhibitory antibody 
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to PSGL-1 also limits inflammation in LPS- and ventilator-induced lung injury models [61]. 
The exact mechanisms through which the SELPLG SNPs exert their functional effect is not 
known it was postulated that alteration in amino acid sequence may result in altered P-
selectin binding affinity and therefore alter neutrophil rolling [61]. 
 
Once tethering and rolling are initiated, integrins play a role in slowing down and 
immobilising neutrophils to allow transendothelial migration and activation [62]. 
Surprisingly, neutralising antibodies to the β2 integrin CD18 in the context of sterile lung 
inflammation results in increased alveolar neutrophils but a reduction in neutrophil-mediated 
pulmonary injury, suggesting that its predominant role is in neutrophil activation rather than 
chemotaxis [13].  β2 integrins on the surface of activated neutrophils induce heparin-binding 
protein (HBP) release through phosphoinositide 3-kinase (PI3K)-dependent signalling [63]. 
Antibody-mediated blockade of β2 integrin function resulted in lower levels of circulating 
HBP and a subsequent reduction in pulmonary oedema, which the authors propose is 
principally through a reduction in vascular leak and endothelial dysfunction [46]. The β2 
integrin binds to intracellular adhesion molecule 1 (ICAM-1) on endothelial cells to aid in 
neutrophil transmigration [64]. Soluble ICAM-1 is elevated in ARDS patients and its 
inhibition reduces sterile lung injury in mice [65,66]. 
 
NETosis 
NETosis, the process through which neutrophils release extracellular DNA in order to trap 
and contain bacteria, is an important defence mechanism against invading pathogens. 
Increased NET production has recently been associated with increased ARDS severity 
[67,68]. Lefrançais et al. demonstrated that circulating neutrophils from ARDS patients 
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produce significantly more NETs upon phorbol myristate acetate stimulation than those from 
healthy donors [68]. As NETs contain and can release neutrophil elastases, myeloperoxidase, 
DNA and histones, they can also potentiate the tissue damage observed in ARDS, in part 
through cytotoxic effects on epithelial and endothelial cells [69]. Reducing NETs either by 
intratracheal DNase I treatment or the partial deficiency of protein arginine deiminase 4 
(PAD4
+/–
; a protein involved in the projection of NETs) increased survival in a mouse model 
of severe bacterial pneumonia/acute lung injury [68]. Although partial deficiency of PAD4 
reduces lung injury, complete knock out increases bacterial burden. This suggests that a NET 
balance is necessary and that the potential deleterious or beneficial effects of NETs in ARDS 
may relate to the presence of microbial infection [68]. Furthermore, a phase III clinical trial is 
currently investigating the effectiveness of inhaled dornase alpha, recombinant human 
DNAse 1, in reducing the incidence of moderate to severe ARDS in severe trauma patients 
through accelerated degradation of extracellular DNA, including NETs (Table 1) [70]. 
 
Granule proteins 
The release of various granule proteins including elastases, matrix metalloproteinases (MMP) 
and cationic polypeptides have been associated with the propagation of ARDS [71]. 
Neutrophil elastases (NE) are implicated in lung injury, although it is unclear whether the 
damage is principally to endothelial or epithelial cells or as a result of degradation of the 
alveolar basement membrane [72,73]. Plasma levels of NE and the endogenous proteinase 
inhibitor elafin are predictors of ARDS mortality [74], while inhibition of NE reduces lung 
injury in various animal models [75–79]. Mice deficient in NE are more susceptible to gram-
negative bacteria, suggesting that NE is required for adequate host defence against invading 
pathogens complete inhibition of NE can be harmful [80]. Despite data from pre-clinical 
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models, sivelestat, a selective NE-inhibitor, does not alter 28-day mortality in a number of 
clinical trials (Table 1) [81]. Although alteration in oxygenation has been observed the small 
sample sizes of the majority of clinical trials and heterogenous patient populations potentially 
mask any benefit in sub-groups of patients with ARDS [81]. It is difficult to separate 
challenges in clinical trial design from limitations of biological importance in this context, 
therefore further study is required to clarify both aspects of this problem.   
 
MMPs are zinc-dependant endopeptidases with numerous biological functions such as tissue 
remodelling, wound healing and angiogenesis [82]. Fligiel and colleagues investigated 
numerous MMPs and their natural antagonists tissue inhibitor of metalloproteinases (TIMPs) 
in BALF fluids of ARDS patients [83]. MMP-2, MMP-8 and MMP-9 are proteases secreted 
by neutrophils and their levels were elevated in all patients along with neutrophil number. 
Furthermore, elevated MMP-1 and MMP-3 was associated with increased mortality [83].  
Although neutrophils do not produce MMP-1 and MMP-3, they can induce MMP-1 secretion 
in human vascular smooth muscle cells which in turn acts in an autocrine feedback loop to 
produce CXCL8 and induce neutrophil chemotaxis [84]. Consistent with this, MMP-3 
deficient mice have reduced neutrophil migration into the lung and attenuated neutrophil-
mediated epithelial and vascular damage in the context of immune complex-mediated 
pulmonary injury [85]. MMP-13 has shown to be play a role in the development of sepsis-
mediated acute lung injury [86]. Hypertonic saline has shown to reduce the production of 
MMPs such as MMP-9 and MMP-13 in mouse models of acute lung injury, thereby reducing 
disease progression and inflammation; an open-label clinical trial is currently underway to 
evaluate efficacy in post-traumatic acute lung injury (Table 1) [86–88].  
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As mentioned previously, HBP is a cationic peptide that plays an important role in 
neutrophil-mediated vascular leakage through increased endothelial permeability [89]. In 
trauma patients admitted to intensive care, early elevation of HBP after admission was a 
predictor for the development of ARDS suggesting that HBP may be a potential biomarker 
for the early detection of ARDS although further work is required [90]. Plasma HBP has also 
been shown to be an independent predictor for 30-day mortality in ARDS [91]. 
Administration of simvastatin to patients with acute lung injury reduced HBP plasma levels 
[92]. Simvastatin did not improve overall survival in ARDS patients, however secondary 
analysis has identified improvement in 28- and 90-day survival in patients with a 
hyperinflammatory subphenotype relative to placebo control (Table 1) [93].   
 
Defensins are arginine-rich cationic proteins which have antimicrobial properties [94]. 
Divided into two subgroups, α-defensins and β-defensins exhibit different roles. Neutrophils 
store α-defensins in their granules and release them in attempt to eradicate microbes, with β-
defensins primarily expressed by mucosal surface epithelial cells. However, defensins can 
also result in tissue damage, as observed in ARDS [95]. Elevated levels of α defensins were 
found in BALF of ARDS patients and higher levels correlate with increased severity of lung 
injury [95]. Although plasma α-defensin was also elevated it did not correlate with prognosis 
- it has been proposed that circulating α-defensin originates from the bone-marrow rather 
than directly from neutrophils and therefore have different functional effects in this context. 
Although not known to be produced by neutrophils, β-defensins are implicated in the 
pathogenesis of ARDS. β-defensin-3 inhibits neutrophil apoptosis by downregulating Bid, a 
pro-apoptotic protein, and upregulating the anti-apoptotic protein Bcl-xL in neutrophils [96]. 
This delay in apoptosis is dependent upon interaction of β-defensin-3 with the chemokine 
receptor CCR6, with the effect attenuated in the presence of a CCR6-specific blocking 
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antibody [96]. As discussed below, delay in neutrophil apoptosis is associated with an 
increased severity in lung injury. 
 
LL-37 is another cationic protein with antimicrobial properties released from neutrophil 
granules [97]. It also carries the ability to activate neutrophils and augment the inflammatory 
cascade [98] and LL-37 is elevated in BALF samples of ARDS patients relative to healthy 
volunteers [97]. Interestingly, although elevated LL-37 correlated with increased lung injury, 
LL-37 did not correlate with neutrophil counts, suggesting that neutrophils are not the only 
source of LL-37 with macrophages and epithelial cell production also described [97]. 
 
Reactive oxygen species 
Reactive oxygen species (ROS) play an important role in eliminating pathogens within 
phagosomes and for the generation of NETs but also act as chemoattractants for immune 
cells resulting in tissue repair [99]. However, excess ROS production results in oxidative 
stress and plays a major role in lung damage through the release of pro-inflammatory 
cytokines, enhanced recruitment of immune cells and consequently the progression of ARDS 
[99]. Neutrophils have been shown to produce ROS when activated and contribute to 
oxidative stress [99]. Furthermore, increased permeability of the endothelial and epithelial 
barrier is observed, increasing neutrophil transmigration to the alveolar space [99]. 
Additionally, an increase in oxidised molecules and reduction in anti-oxidant proteins is 
observed in BALF fluid of ARDS patients which serves to perpetuate lung damage [100]. 
Glutathione plays a vital role in neutralising hydrogen peroxide, a major contributor to 
oxidative damage, through the enzyme glutathione peroxidase by converting glutathione to 
glutathione disulphide [101]. Administration of the anti-oxidant N-acetylcysteine restores the 
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oxidant balance by increasing glutathione levels in erythrocytes. Several clinical trials have 
investigated the role of N-acetylcysteine as a therapeutic strategy in ARDS with variable 
results. A recent meta-analysis concluded that, although duration of intensive care admission 
is shortened, there is no demonstrable effect on overall outcome or 30-day survival [102].    
 
Mechanisms of cell death 
In addition to marked inflammatory cell activation and recruitment, the pathogenesis of 
ARDS is characterized by alterations in a variety of forms of cell death. Death and damage to 
the alveolar epithelial and alveolar endothelial cells is thought to play a key role in the 
initiation and progression of the disease process [103,104], while inflammatory cell apoptosis 
and subsequent clearance is an important step in inflammation resolution [105,106]. While 
apoptosis (described further below) is undoubtedly the most studied form of cell death, there 
has also been a recent ‘-osis explosion’ with increased knowledge of alternative cell death 
pathways such as pyroptosis, necroptosis, ferroptosis, entosis and NETosis [107]. While 
some of these non-apoptotic pathways are likely to have relevance to the pathogenesis of 
ARDS, this is an as yet understudied area that will hopefully lead to future novel avenues for 
therapeutic intervention.  
 
Targeting apoptosis 
Apoptosis occurs through two distinct but converging pathways. The intrinsic pathway is 
activated in response to diverse stimuli including DNA damage, ROS exposure and 
endoplasmic reticulum stress. The central event in intrinsic apoptosis is mitochondrial outer 
membrane permeabilization that allows escape of pro-apoptotic molecules such as 
cytochrome-c which then form a caspase-activating complex. Active caspases act as the 
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executioners of apoptosis leading to cellular disassembly of the cell, DNA degradation, cell 
surface phosphatidylserine exposure and pannexin channel activation, all hallmarks of 
apoptotic cell death. Mitochondrial outer membrane permeabilization is itself controlled by 
intracellular Bcl2 family proteins which includes both pro- and anti-apoptotic members (such 
as Bid and Bcl-xL, described above). In contrast, extrinsic apoptosis is usually activated by a 
cell surface death receptor upon interaction with its cognate ligand which then leads to 
caspase activation. The multiple steps and checkpoints involved in apoptotic cell death both 
allow this to be dysregulated at multiple steps in human diseases such as ARDS, but also 
allows the potential for therapeutic intervention at several levels [108].  
 
Neutrophil apoptosis in ARDS has been shown to be delayed by several groups including our 
own [109–112] and correlates with disease severity in sepsis and sepsis-related ARDS. 
Interestingly, BALF from patients with early ARDS (days 1 and 3 of disease) but not late 
ARDS directly inhibits apoptosis of healthy donor neutrophils [109]. This effect has been 
attributed to soluble factors including GM-CSF, G-CSF, CXCL8 and IL-2 [109,113]. Recent 
detailed phenotyping of ARDS neutrophils has revealed multiple phenotypic alterations 
alongside delayed apoptosis [112]. Interestingly, ARDS BALF-induced delay of healthy 
neutrophil apoptosis could be overcome by PI3K inhibition, whereas the anti-apoptosis 
phenotype of ARDS patient neutrophils was resistant to PI3K inhibition [112]. This suggests 
that additional PI3K-independent mechanisms are in play within the complex pro-
inflammatory milieu experienced during human ARDS.  
 
Several other pre-clinical strategies targeting neutrophil apoptosis have also shown promise 
in the treatment of lung injury. Targeting of the extrinsic pathway of apoptosis has been 
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achieved by TRAIL (TNF-related apoptosis-inducing ligand), part of the TNF family of 
ligands that can initiate apoptosis by activating cell surface receptors [114]. TRAIL appears 
to have no role in constitutive neutrophil apoptosis nor neutrophil chemotaxis (in contrast to 
the TNF family ligand FasL which is a potent neutrophil chemoattractant). However, in 
response to LPS-induced lung injury, TRAIL acts to limit inflammation and enhances 
neutrophil apoptosis [115]. Furthermore, recombinant TRAIL was able to induce an anti-
inflammatory response, suggesting such strategies may have therapeutic potential in human 
ARDS. Targeting of the intrinsic pathway of neutrophil apoptosis, such as with cyclin-
dependent kinase inhibitor (CDKi) drugs, has also been shown to have potent anti-
inflammatory effects in animal models of neutrophil dominant inflammation [14,15]. CDKi 
drugs principally induce neutrophil apoptosis by inhibiting CDK9-mediated transcription of 
the short lived Bcl2 member Mcl-1 [14,116]. As neutrophils have limited expression of the 
main anti-apoptotic Bcl2 homologue, Bcl2 itself, this leaves them sensitive to alterations in 
Mcl-1 leading to apoptosis. CDKi drugs enhance resolution of several lung injury models 
including bleomycin-induced, endotoxin-induced and bacteria-induced lung injury [14,117]. 
Interestingly, in an Escherichia coli-induced model of acute lung injury, a CDKi drug 
administered after the onset of inflammation augmented the resolution of lung inflammation 
without detrimentally reducing clearance of the bacteria. Indeed, there was increased 
bacterial clearance possibly resulting from lipid-mediated enhanced bacterial phagocytosis by 
macrophages [14].  Furthermore, and in contrast to that observed with PI3K inhibition [112], 
CDKi has recently been shown to override the delayed neutrophil apoptosis in sepsis-induced 
human ARDS concurrent with reduced expression of Mcl-1 [111]. This suggests that Mcl-1 
targeting approaches (either with CDKi or with use of novel small molecule Mcl-1 inhibitors) 
may have therapeutic potential in human ARDS. 
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Other strategies to modulate neutrophil apoptosis warrant further investigation in the context 
of ARDS. Potential strategies include the use of a p21 (Cdnk1a) peptide which binds and 
sequesters proliferating cell nuclear antigen (PCNA), an important endogenous neutrophil 
anti-apoptotic factor [118]. While p21 peptide is able to induce apoptosis of neutrophils 
isolated from patients with lung inflammation [119], testing in in vivo models of ARDS is 
awaited. Several families of anti-inflammatory lipid mediators which influence neutrophil 
lifespan and their clearance (amongst other pleiotropic effects) have also been delineated. 
These include the lipids 15-epi-lipoxin A4 and resolvin E1 which drive neutrophil apoptosis 
and attenuate experimental lung injury [120,121]. 
 
Lung parenchymal cell death 
In contrast to the potential benefits of inflammatory cell apoptosis during lung injury, there is 
also evidence that damage and death of the lung epithelium and endothelium can contribute 
to disease pathogenesis [109]. Alveolar epithelial apoptosis is observed in experimental lung 
injury caused by bleomycin, endotoxin and acid [31,122], while alterations in Bcl2 members 
(including increases in pro-apoptotic Bax) have been observed in lung epithelium from 
human lung injury cases [123]. In addition, BALF from human ARDS patients contains FasL 
which activates Fas receptor to induce extrinsic pathway apoptosis [124]. Lung epithelium 
expresses Fas, with ARDS BALF able to induce epithelial apoptosis in a Fas/FasL-dependent 
fashion [124], but abolished Fas activity was unable to protect in experimental virus-induced 
ARDS [125]. Further work is needed to clarify the role and timing of Fas/FasL strategies, 
especially as Fas can also influence macrophage dynamics during resolution of lung injury 
[126]. 
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Similarly, death of pulmonary endothelium has recently been demonstrated to be a 
pathogenic response in endotoxin-induced lung injury [127]. This elegant study demonstrated 
that endotoxin exposure led to activation of caspase-4/5 (caspase-11 in mice) in endothelium 
and a consequent pro-inflammatory, lytic form of cell death (termed pyroptosis). Conditional 
deletion of caspase-11 specifically in endothelial cells (using a Cre/lox system) led to reduced 
endotoxin-induced lung oedema, neutrophil accumulation and death. Caspase-11 inhibitors 
such as wedololactone suppress endotoxin-induced caspase-11 in vitro [128] but their role in 
lung injury in vivo remains to be tested. In summary, any potential anti-inflammatory strategy 
based on modulation of inflammatory cell death has to carefully balance potentially 
deleterious off-target effects should cell death be induced in lung parenchymal cells. 
 
Clearance of apoptotic cells 
Macrophages play a crucial role in limiting excessive inflammation and augmenting tissue 
repair, not only in the clearance of apoptotic and necrotic cells, but also removal of 
neutrophils undergoing NETosis [129,130]. In ARDS, however, macrophage phagocytic 
function is impaired [130]. Grégoire and colleagues observed enhanced NET formation and 
reduced neutrophil apoptosis coupled with a reduction in macrophage clearance of apoptotic 
cells (efferocytosis) in BALF from ARDS patients [130]. AMP-activated protein kinase 
(AMPK) has been associated with increasing macrophage phagocytosis and reduced TNF and 
IL-6 production [131]. The addition of metformin, an AMPK activator, to ARDS BALF 
samples resulted in removal of NETs and increased efferocytosis by macrophages [130]. 
Additionally, AMPK activators administered in an LPS-induced mouse lung injury model 
reduced alveolar neutrophil accumulation, pulmonary oedema and BALF TNF and IL-6. 
Furthermore, retrospective analysis of diabetic patients on metformin for the three months 
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prior to developing ARDS had a non-significant reduction in 30-day mortality from 55.32% 
to 42.42%.  Little is known about the exact anti-inflammatory mechanism of metformin in 
this context and therefore requires further study [132].  
 
A similar observation was made using a neutralising antibody against HMGB1 to increase 
macrophage efferocytosis [130]. HMGB1, which is increased in ARDS [133], inhibits 
efferocytosis by interfering with the binding between the phosphatidylserine bridging 
molecule milk fat globule EGF factor 8 (MFG-E8) and the αvβ3 integrin on the surface of 
macrophages [134]. Importantly, MFG-E8 knockout mice have increased apoptotic alveolar 
neutrophils in the alveolar space following LPS-induced injury, an effect that can be rescued 
by recombinant MFG-E8 [135].  
 
Another potential mechanism which some have speculated may be involved in neutrophil 
clearance is the relatively recently described concept of reverse migration. This is the process 
by which neutrophils migrate in the opposite direction to the chemotactic gradients that 
initially recruited them [136,137]. As yet this process has only been demonstrated in 
zebrafish and mouse models, with no firm data demonstrating a direct role in human disease. 
In animal models, prostaglandin E2 (PGE2) is an important mediator of neutrophil reverse 
migration with macrophage depletion resulting in inhibited reverse migration and therefore 
delayed resolution of inflammation due to reduced PGE2 production [138]. Additionally, 
PGE2 depletion has a similar effect, further validating its importance in resolution. PGE2 
signals through the EP4 receptor, increasing Alox12 production and consequently lipoxin A4, 
an important pro-resolving mediator which enhances reverse migration [138]. In the context 
of resolution of pulmonary inflammation in mice, LTB4 released by neutrophils promotes 
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neutrophil elastase release, which subsequently cleaves junctional adhesion molecule-C 
(JAM-C) from the endothelium of post-capillary venules facilitating reverse migration of 
neutrophils [139]. Although the departure of neutrophils from sites of inflammation can be 
considered a sign of inflammatory resolution, reverse migration also has the potential to 
propagate inflammation. Local ischaemia-reperfusion to the ear skin or cremaster muscle in 
mice can progress to a systemic inflammatory response in numerous organs including the 
lung, heart and liver [139]. Pharmacological or genetic interference to either enhance or 
inhibit reverse migration led to a parallel increase or decrease in secondary inflammation in 
the lung distant organs [139]. In humans, increased levels of soluble JAM-C were detected in 
the plasma of ARDS patients, hinting that reverse migration may be occurring with a 
significant direct correlation observed between soluble JAM-C and the severity of multi-
organ failure [139]. These data therefore suggest that neutrophil reverse migration may not be 
simply a clearance mechanism but has the potential to cause dysregulated systemic pro-
inflammation in ARDS.   
 
Conclusion  
Neutrophils are both a hallmark and driver of ARDS acting in concert with other resident and 
recruited inflammatory cell types to induce a dysregulated, overwhelming and often fatal pro-
inflammatory state within the lung (Figure 1). To conclude that a simple “one-size fits all” 
approach in the context of both the pathogenesis and potential therapeutics is perhaps naive 
and out-dated. This conclusion is supported by the identification of distinct sub-populations 
of ARDS patients who respond differently to fluid management, ventilation strategies and 
some pharmacological therapies [93,140,141]. Recognition of these different hypo- and 
hyper-inflammatory phenotypes within the ARDS cohort as well as ever-increasing numbers 
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of predictive and prognostic biomarkers is leading to a shift in clinical trial design to reduce 
clinical and biological heterogeneity [3]. New combination therapies that target a variety of 
inflammatory components in ARDS are also being considered to address issues of 
redundancy, as are cell based therapies including bone marrow derived myeloid suppressor 
cells in infection-related ARDS [3].   
 
It is therefore essential that variations in neutrophil phenotype and function as well as 
understanding of neutrophil behaviour in different patient cohorts is explored and 
characterised. As has been outlined, the difficulties of neutrophil-specific therapies in the 
context of infection-related ARDS warrants further exploration but, as in the context of 
induction of neutrophil apoptosis, this should not stop further investigation particularly in the 
context of combination therapies. Further research is also required on the complex chemokine 
networks, NETosis, mechanisms of inflammation resolution as well as strategies that aim to 
protect or enhance repair of damaged epithelial and endothelial beds. It is now over fifty 
years since ARDS was first described [142] and much has been learnt about its pathogenesis 
and beneficial supportive ventilation and fluid management strategies but the era of effective 
pharmacological treatments is yet to dawn. Targeting aspects of neutrophil biology is likely 
to have a place among those therapies. 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
Acknowledgements 
Funding is acknowledged from EPSRC/MRC (PP), MRC (MR/K013386/1; AGR), The 
Wellcome Trust (206566/Z/17/Z; CDL) and Pathological Society (1147, TSGS 2016 10 04; 
DAD). 
 
Author contribution 
All authors contributed to manuscript writing and revision. All authors approved the final 
version. 
 
List of abbreviations: 
AMPK, AMP-activated protein kinase; 
ARDS, acute respiratory distress syndrome; 
BALF, bronchoalveolar lavage fluid;  
BLT2, leukotriene B4 receptor 2; 
CCL/CXCL, chemokine ligands;  
CDK, cyclin dependent kinase; 
CDKi, cyclin-dependent kinase inhibitor; 
CXCR, chemokine receptor;  
DBP, Vitamin D binding protein;  
FPR, formyl peptide receptor; 
G-CSF, granulocyte-colony stimulating factor; 
GM-CSF, granulocyte/macrophage-stimulating factor;  
HBP, heparin- binding protein;  
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
HMGB1, high mobility group box; 
IL, interleukin;  
ICAM-1, intracellular adhesion molecule 1; 
JAM-C, junctional adhesion molecule-C; 
LPS, lipopolysaccharide; 
LTB4, leukotriene B4;  
MFG-E8, milk fat globule EGF factor 8; 
MMP, matrix metalloproteinase;  
NE, neutrophil elastases; 
NET, neutrophil extracellular trap; 
NLR, Nod-like receptor; 
PGE2, prostaglandin E2; 
PI3K, Phosphoinositide 3-kinase;  
PAD4, protein arginine deiminase 4; 
PAI, Plasminogen activator inhibitor; 
PAMP, pathogen-associated molecular pattern;  
PRR, pathogen recognition receptor;  
ROS, reactive oxygen species; 
SELPG, Selectin P ligand gene; 
SNP, single nucleotide polymorphism;  
TIMP, tissue inhibitors of metalloproteinases;  
TLR, toll-like receptor; 
TNF, tumour necrosis factor;  
TRAIL, TNF-related apoptosis-inducing ligand 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
References 
1  ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, et al. Acute Respiratory 
Distress Syndrome. JAMA 2012; 307: 2526-2533. 
2  Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, and mortality for 
patients with acute respiratory distress syndrome in intensive care units in 50 
countries. JAMA 2016; 315: 788-800. 
3  Matthay MA, McAuley DF, Ware LB. Clinical trials in acute respiratory distress 
syndrome: challenges and opportunities. Lancet Respir Med 2017; 5: 524-534. 
4  Thompson BT, Chambers RC, Liu KD. Acute Respiratory Distress Syndrome. N Engl 
J Med 2017; 377: 562-572. 
5  Esteban A, Fernández-Segoviano P, Frutos-Vivar F, et al. Comparison of clinical 
criteria for the acute respiratory distress syndrome with autopsy findings. Ann Intern 
Med 2004; 141: 440-445. 
6  Zheng S, D’Souza VK, Bartis D, et al. Lipoxin A4 promotes lung epithelial repair 
whilst inhibiting fibroblast proliferation. ERJ Open Res 2016; 2: 00079-2015. 
7  Gao Y, Zhang H, Luo L, et al. Resolvin D1 improves the resolution of inflammation 
via activating nf-κb p50/p50–mediated cyclooxygenase-2 expression in acute 
respiratory distress syndrome. J Immunol 2017; 199: 2043-2054. 
8  Burnham EL, Janssen WJ, Riches DWH, et al. The fibroproliferative response in acute 
respiratory distress syndrome: mechanisms and clinical significance. Eur Respir J 
2014; 43: 276-285. 
9  Grommes J, Soehnlein O. Contribution of neutrophils to acute lung injury. Mol Med 
2011; 17: 293-307. 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
10  Williams AE, Chambers RC. The mercurial nature of neutrophils: still an enigma in 
ARDS? Am J Physiol Cell Mol Physiol 2014; 306: L217-L230. 
11  Steinberg KP, Milberg JA, Martin TR, et al. Evolution of bronchoalveolar cell 
populations in the adult respiratory distress syndrome. Am J Respir Crit Care Med 
1994; 150: 113-122. 
12  Abraham E, Carmody A, Shenkar R, et al. Neutrophils as early immunologic effectors 
in hemorrhage- or endotoxemia-induced acute lung injury. Am J Physiol Cell Mol 
Physiol 2000; 279: L1137-L1145. 
13  Folkesson HG, Matthay MA, Hébert CA, et al. Acid aspiration-induced lung injury in 
rabbits is mediated by interleukin-8-dependent mechanisms. J Clin Invest 1995; 96: 
107-116. 
14  Lucas CD, Dorward DA, Tait MA, et al. Downregulation of Mcl-1 has anti-
inflammatory pro-resolution effects and enhances bacterial clearance from the lung. 
Mucosal Immunol 2014; 7: 857-868. 
15  Rossi AG, Sawatzky DA, Walker A, et al. Cyclin-dependent kinase inhibitors enhance 
the resolution of inflammation by promoting inflammatory cell apoptosis. Nat Med 
2006; 12: 1056-1064. 
16  Zeiher BG, Artigas A, Vincent J-L, et al. Neutrophil elastase inhibition in acute lung 
injury: results of the STRIVE study. Crit Care Med 2004; 32: 1695-1702. 
17  Mantovani A, Cassatella MA, Costantini C, et al. Neutrophils in the activation and 
regulation of innate and adaptive immunity. Nat Rev Immunol 2011; 11: 519-531. 
18  Nourshargh S, Alon R. Leukocyte migration into inflamed tissues. Immunity 2014; 41: 
694-707. 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
19  Deniset JF, Kubes P. Recent advances in understanding neutrophils. F1000Research 
2016; 5: 2912. 
20  Scott BN V, Kubes P. Death to the neutrophil! A resolution for acute respiratory 
distress syndrome? Eur Respir J 2018; 52: 1801274. 
21  Han S, Mallampalli RK. The acute respiratory distress syndrome: from mechanism to 
translation. J Immunol 2015; 194: 855-860. 
22  Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int 
Rev Immunol 2011; 30: 16-34. 
23  Ramírez Cruz NE, Maldonado Bernal C, Cuevas Urióstegui ML, et al. Toll-like 
receptors: dysregulation in vivo in patients with acute respiratory distress syndrome. 
Rev Alerg Mex 51: 210-217. 
24  Prince LR, Whyte MK, Sabroe I, et al. The role of TLRs in neutrophil activation. Curr 
Opin Pharmacol 2011; 11: 397-403. 
25  Bakopoulos A, Kapelouzou A, Tsilimigras DI, et al. Expression of Toll-like receptors 
(TLRs) in the lungs of an experimental sepsis mouse model. PLoS One 2017; 12: 
e0188050. 
26  Hoth JJ, Wells JD, Brownlee NA, et al. Toll-like receptor 4-dependent responses to 
lung injury in a murine model of pulmonary contusion. Shock 2009; 31: 376-381. 
27  Hilberath JN, Carlo T, Pfeffer MA, et al. Resolution of Toll-like receptor 4-mediated 
acute lung injury is linked to eicosanoids and suppressor of cytokine signaling 3. 
FASEB J 2011; 25: 1827-1835. 
28  Tolle LB, Standiford TJ. Danger-associated molecular patterns (DAMPs) in acute lung 
injury. J Pathol 2013; 229: 145-156. 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
29  Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause 
inflammatory responses to injury. Nature 2010; 464: 104-107. 
30  Nakahira K, Kyung S-Y, Rogers AJ, et al. Circulating mitochondrial DNA in patients 
in the ICU as a marker of mortality: derivation and validation. PLoS Med 2013; 10: 
e1001577; discussion e1001577. 
31  Dorward DA, Lucas CD, Doherty MK, et al. Novel role for endogenous mitochondrial 
formylated peptide-driven formyl peptide receptor 1 signalling in acute respiratory 
distress syndrome. Thorax 2017; 72: 928-936. 
32  Dorward DA, Lucas CD, Chapman GB, et al. The role of formylated peptides and 
formyl peptide receptor 1 in governing neutrophil function during acute inflammation. 
Am J Pathol 2015; 185: 1172-1184. 
33  Gao JL, Lee EJ, Murphy PM. Impaired antibacterial host defense in mice lacking the 
N-formylpeptide receptor. J Exp Med 1999; 189: 657-662. 
34  Zhang X, Wang T, Yuan Z-C, et al. Mitochondrial peptides cause proinflammatory 
responses in the alveolar epithelium via FPR-1, MAPKs, and AKT: a potential 
mechanism involved in acute lung injury. Am J Physiol Cell Mol Physiol September 
2018: ajplung.00466.2017. 
35  Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning 
cells for host defense and immunity. Annu Rev Immunol 2014; 32: 659-702. 
36  Donnelly SC, Strieter RM, Kunkel SL, et al. Interleukin-8 and development of adult 
respiratory distress syndrome in at-risk patient groups. Lancet 1993; 341: 643-647. 
37  Groeneveld AB, Raijmakers PG, Hack CE, et al. Interleukin 8-related neutrophil 
elastase and the severity of the adult respiratory distress syndrome. Cytokine 1995; 7: 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
746-752. 
38  Miller EJ, Cohen AB, Nagao S, et al. Elevated levels of nap-1/interleukin-8 are present 
in the airspaces of patients with the adult respiratory distress syndrome and are 
associated with increased mortality. Am Rev Respir Dis 1992; 146: 427-432. 
39  Williams AE, José RJ, Mercer PF, et al. Evidence for chemokine synergy during 
neutrophil migration in ARDS. Thorax 2017; 72: 66-73. 
40  Puneet P, Moochhala S, Bhatia M. Chemokines in acute respiratory distress syndrome. 
Am J Physiol Cell Mol Physiol 2005; 288: L3-L15. 
41  Finsterbusch M, Voisin M-B, Beyrau M, et al. Neutrophils recruited by 
chemoattractants in vivo induce microvascular plasma protein leakage through 
secretion of TNF. J Exp Med 2014; 211: 1307-1314. 
42  Guma M, Ronacher L, Liu-Bryan R, et al. Caspase 1-independent activation of 
interleukin-1beta in neutrophil-predominant inflammation. Arthritis Rheum 2009; 60: 
3642-3650. 
43  Proudfoot A, Bayliffe A, O’Kane CM, et al. Novel anti-tumour necrosis factor 
receptor-1 (TNFR1) domain antibody prevents pulmonary inflammation in 
experimental acute lung injury. Thorax 2018; 73: 723-730. 
44  Vermeij J-D, Aslami H, Fluiter K, et al. Traumatic brain injury in rats induces lung 
injury and systemic immune suppression. J Neurotrauma 2013; 30: 2073-2079. 
45  Lechner AJ, Tredway TL, Brink DS, et al. Differential systemic and intrapulmonary 
TNF-alpha production in Candida sepsis during immunosuppression. Am J Physiol 
1992; 263: L526-35. 
46  Bird MD, Kovacs EJ. Organ-specific inflammation following acute ethanol and burn 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
injury. J Leukoc Biol 2008; 84: 607-613. 
47  Humphries DC, O’Neill S, Scholefield E, et al. Cerebral concussion primes the lungs 
for subsequent neutrophil-mediated injury. Crit Care Med 2018; 46: e937-e944. 
48  Nongnuch A, Panorchan K, Davenport A. Brain-kidney crosstalk. Crit Care 2014; 18: 
225. 
49  Villapol S. Consequences of hepatic damage after traumatic brain injury: current 
outlook and potential therapeutic targets. Neural Regen Res 2016; 11: 226-227. 
50  Goodman RB, Pugin J, Lee JS, et al. Cytokine-mediated inflammation in acute lung 
injury. Cytokine Growth Factor Rev 2003; 14: 523-535. 
51  Park WY, Goodman RB, Steinberg KP, et al. Cytokine balance in the lungs of patients 
with Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med 2001; 164: 
1896-1903. 
52  Peter JV, John P, Graham PL, et al. Corticosteroids in the prevention and treatment of 
acute respiratory distress syndrome (ARDS) in adults: meta-analysis. BMJ 2008; 336: 
1006-1009. 
53  Weigelt JA, Norcross JF, Borman KR, et al. Early steroid therapy for respiratory 
failure. Arch Surg 1985; 120: 536-540. 
54  Frieri M. Corticosteroid effects on cytokines and chemokines. Allergy Asthma Proc 
1999; 20: 147-160. 
55  Steinberg KP, Hudson LD, Goodman RB, et al. Efficacy and safety of corticosteroids 
for persistent acute respiratory distress syndrome. N Engl J Med 2006; 354: 1671-
1684. 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
56  Meduri GU, Bridges L, Shih M-C, et al. Prolonged glucocorticoid treatment is 
associated with improved ARDS outcomes: analysis of individual patients’ data from 
four randomized trials and trial-level meta-analysis of the updated literature. Intensive 
Care Med 2016; 42: 829-840. 
57  Donnelly SC, Haslett C, Dransfield I, et al. Role of selectins in development of adult 
respiratory distress syndrome. Lancet 1994; 344: 215-219. 
58  Lawrence MB, Springer TA. Neutrophils roll on E-selectin. J Immunol 1993; 151: 
6338-6346. 
59  Okajima K, Harada N, Sakurai G, et al. Rapid assay for plasma soluble E-selectin 
predicts the development of acute respiratory distress syndrome in patients with 
systemic inflammatory response syndrome. Transl Res 2006; 148: 295-300. 
60  Sakamaki F, Ishizaka A, Handa M, et al. Soluble form of P-selectin in plasma is 
elevated in acute lung injury. Am J Respir Crit Care Med 1995; 151: 1821-1826. 
61  Bime C, Pouladi N, Sammani S, et al. Genome-wide association study in African 
Americans with acute respiratory distress syndrome identifies the Selectin P ligand 
gene as a risk factor. Am J Respir Crit Care Med 2018; 197: 1421-1432. 
62  Abram CL, Lowell CA. The ins and outs of leukocyte integrin signaling. Annu Rev 
Immunol 2009; 27: 339-362. 
63  Liu Y, Ma S, Wang X, et al. The role of β2 integrin associated heparin-binding protein 
release in ARDS. Life Sci 2018; 203: 92-98. 
64  Oberyszyn TM, Conti CJ, Ross MS, et al. Beta2 integrin/ICAM-1 adhesion molecule 
interactions in cutaneous inflammation and tumor promotion. Carcinogenesis 1998; 
19: 445-455. 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
65  Agouridakis P, Kyriakou D, Alexandrakis MG, et al. The predictive role of serum and 
bronchoalveolar lavage cytokines and adhesion molecules for acute respiratory distress 
syndrome development and outcome. Respir Res 2002; 3: 27. 
66  Doerschuk CM, Quinlan WM, Doyle NA, et al. The role of P-selectin and ICAM-1 in 
acute lung injury as determined using blocking antibodies and mutant mice. J Immunol 
1996; 157: 4609-4614. 
67  Li H, Zhou X, Tan H, et al. Neutrophil extracellular traps contribute to the 
pathogenesis of acid-aspiration-induced ALI/ARDS. Oncotarget 2018; 9: 1772-1784. 
68  Lefrançais E, Mallavia B, Zhuo H, et al. Maladaptive role of neutrophil extracellular 
traps in pathogen-induced lung injury. JCI insight 2018; 3: 98178. 
69  Saffarzadeh M, Juenemann C, Queisser MA, et al. Neutrophil extracellular traps 
directly induce epithelial and endothelial cell death: A predominant role of histones. 
PLoS One 2012; 7: e32366. 
70  Pottecher J. Inhaled dornase alpha to reduce respiratory failure after severe trauma - 
https://clinicaltrials.gov/ct2/show/NCT03368092 
71  Frantzeskaki F, Armaganidis A, Orfanos SE. Immunothrombosis in acute respiratory 
distress syndrome: Cross talks between inflammation and coagulation. Respiration 
2017; 93: 212-225. 
72  Carden D, Xiao F, Moak C, et al. Neutrophil elastase promotes lung microvascular 
injury and proteolysis of endothelial cadherins. Am J Physiol 1998; 275: H385-392. 
73  Ginzberg HH, Cherapanov V, Dong Q, et al. Neutrophil-mediated epithelial injury 
during transmigration: role of elastase. Am J Physiol Liver Physiol 2001; 281: G705-
G717. 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
74  Wang T, Zhu Z, Liu Z, et al. Plasma neutrophil elastase and elafin as prognostic 
biomarker for acute respiratory distress syndrome. Shock 2017; 48: 168-174. 
75  Tkalcevic J, Novelli M, Phylactides M, et al. Impaired immunity and enhanced 
resistance to endotoxin in the absence of neutrophil elastase and cathepsin G. Immunity 
2000; 12: 201-210. 
76  Kawabata K, Hagio T, Matsumoto S, et al. Delayed neutrophil elastase inhibition 
prevents subsequent progression of acute lung injury induced by endotoxin inhalation 
in hamsters. Am J Respir Crit Care Med 2000; 161: 2013-2018. 
77  Hilgendorff A, Parai K, Ertsey R, et al. Neonatal mice genetically modified to express 
the elastase inhibitor elafin are protected against the adverse effects of mechanical 
ventilation on lung growth. Am J Physiol Lung Cell Mol Physiol 2012; 303: L215-227. 
78  Fujino N, Kubo H, Suzuki T, et al. Administration of a specific inhibitor of neutrophil 
elastase attenuates pulmonary fibrosis after acute lung injury in mice. Exp Lung Res 
2012; 38: 28-36. 
79  Tagami T, Tosa R, Omura M, et al. Effect of a selective neutrophil elastase inhibitor 
on mortality and ventilator-free days in patients with increased extravascular lung 
water: a post hoc analysis of the PiCCO Pulmonary Edema Study. J Intensive Care 
2014; 2: 67. 
80  Belaaouaj A, McCarthy R, Baumann M, et al. Mice lacking neutrophil elastase reveal 
impaired host defense against gram negative bacterial sepsis. Nat Med 1998; 4: 615-
618. 
81  Pu S, Wang D, Liu D, et al. Effect of sivelestat sodium in patients with acute lung 
injury or acute respiratory distress syndrome: a meta-analysis of randomized 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
controlled trials. BMC Pulm Med 2017; 17: 148. 
82  Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of 
tissue remodelling. Nat Rev Mol Cell Biol 2007; 8: 221-233. 
83  Fligiel SEG, Standiford T, Fligiel HM, et al. Matrix metalloproteinases and matrix 
metalloproteinase inhibitors in acute lung injury. Hum Pathol 2006; 37: 422-430. 
84  Estrada-Gutierrez G, Cappello RE, Mishra N, et al. Increased expression of matrix 
metalloproteinase-1 in systemic vessels of preeclamptic women: a critical mediator of 
vascular dysfunction. Am J Pathol 2011; 178: 451-460. 
85  Nerusu KC, Warner RL, Bhagavathula N, et al. Matrix metalloproteinase-3 
(stromelysin-1) in acute inflammatory tissue injury. Exp Mol Pathol 2007; 83: 169-
176. 
86  Wohlauer M, Moore EE, Silliman CC, et al. Nebulized hypertonic saline attenuates 
acute lung injury following trauma and hemorrhagic shock via inhibition of matrix 
metalloproteinase-13. Crit Care Med 2012; 40: 2647-2653. 
87  Petroni RC, Biselli PJC, de Lima TM, et al. Hypertonic saline (NaCl 7.5%) reduces 
LPS-induced acute lung injury in rats. Inflammation 2015; 38: 2026-2035. 
88  Moore E. A clinical trial to determine if nebulized hypertonic saline attenuates acute 
lung injury following trauma and hemorrhagic shock. 
https://clinicaltrials.gov/ct2/show/NCT01667666 (last updated February 2018). 
89  Bentzer P, Fisher J, Kong HJ, et al. Heparin-binding protein is important for vascular 
leak in sepsis. Intensive Care Med Exp 2016; 4: 33. 
90  Johansson J, Brattström O, Sjöberg F, et al. Heparin-binding protein (HBP): an early 
marker of respiratory failure after trauma? Acta Anaesthesiol Scand 2013; 57: 580-
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
586. 
91  Lin Q, Shen J, Shen L, et al. Increased plasma levels of heparin-binding protein in 
patients with acute respiratory distress syndrome. Crit Care 2013; 17: R155. 
92  McAuley DF, O’Kane CM, Craig TR, et al. Simvastatin decreases the level of heparin-
binding protein in patients with acute lung injury. BMC Pulm Med 2013; 13: 47. 
93  Calfee CS, Delucchi KL, Sinha P, et al. Acute respiratory distress syndrome 
subphenotypes and differential response to simvastatin: secondary analysis of a 
randomised controlled trial. Lancet Respir Med 2018; 6: 691-698. 
94  Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol 2003; 
3: 710-720. 
95  Ashitani J, Mukae H, Arimura Y, et al. High concentrations of α-defensins in plasma 
and bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome. 
Life Sci 2004; 75: 1123-1134. 
96  Nagaoka I, Niyonsaba F, Tsutsumi-Ishii Y, et al. Evaluation of the effect of human  -
defensins on neutrophil apoptosis. Int Immunol 2008; 20: 543-553. 
97  Fahy RJ, Wewers MD. Pulmonary defense and the human cathelicidin hCAP-18/LL-
37. Immunol Res 2005; 31: 075-090. 
98  Tripathi S, Wang G, White M, et al. Identifying the critical domain of ll-37 involved in 
mediating neutrophil activation in the presence of influenza virus: functional and 
structural analysis. PLoS One 2015; 10: e0133454. 
99  Kellner M, Noonepalle S, Lu Q, et al. ROS signaling in the oathogenesis of acute lung 
injury (ALI) and acute respiratory distress syndrome (ARDS). Adv Exp Med Biol 
2017; 967: 105-137. 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
100  Baldwin SR, Simon RH, Grum CM, et al. Oxidant activity in expired breath of 
patients with adult respiratory distress syndrome. Lancet 1986; 1: 11-14. 
101  Soltan-Sharifi MS, Mojtahedzadeh M, Najafi A, et al. Improvement by N-
acetylcysteine of acute respiratory distress syndrome through increasing intracellular 
glutathione, and extracellular thiol molecules and anti-oxidant power: Evidence for 
underlying toxicological mechanisms. Hum Exp Toxicol 2007; 26: 697-703. 
102  Zhang Y, Ding S, Li C, et al. Effects of N-acetylcysteine treatment in acute respiratory 
distress syndrome: A meta-analysis. Exp Ther Med 2017; 14: 2863-2868. 
103  Matute-Bello G, Martin TR. Science review: apoptosis in acute lung injury. Crit Care 
2003; 7: 355-358. 
104  Tang PS, Mura M, Seth R, et al. Acute lung injury and cell death: how many ways can 
cells die? Am J Physiol Lung Cell Mol Physiol 2008; 294: L632-641. 
105  Poon IKH, Lucas CD, Rossi AG, et al. Apoptotic cell clearance: basic biology and 
therapeutic potential. Nat Rev Immunol 2014; 14: 166-180. 
106  Alessandri AL, Sousa LP, Lucas CD, et al. Resolution of inflammation: mechanisms 
and opportunity for drug development. Pharmacol Ther 2013; 139: 189-212. 
107  Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: 
recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death 
Differ 2018; 25: 486-541. 
108  Duffin R, Leitch AE, Fox S, et al. Targeting granulocyte apoptosis: mechanisms, 
models, and therapies. Immunol Rev 2010; 236: 28-40. 
109  Matute-Bello G, Liles WC, Radella F, et al. Modulation of neutrophil apoptosis by 
granulocyte colony-stimulating factor and granulocyte/macrophage colony-stimulating 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
factor during the course of acute respiratory distress syndrome. Crit Care Med 2000; 
28: 1-7. 
110  Fialkow L, Fochesatto Filho L, Bozzetti MC, et al. Neutrophil apoptosis: a marker of 
disease severity in sepsis and sepsis-induced acute respiratory distress syndrome. Crit 
Care 2006; 10: R155. 
111  Dorward DA, Felton JM, Robb CT, et al. The cyclin-dependent kinase inhibitor 
AT7519 accelerates neutrophil apoptosis in sepsis-related acute respiratory distress 
syndrome. Thorax 2017; 72: 182-185. 
112  Juss JK, House D, Amour A, et al. Acute respiratory distress syndrome neutrophils 
have a distinct phenotype and are resistant to phosphoinositide 3-kinase inhibition. Am 
J Respir Crit Care Med 2016; 194: 961-973. 
113  Aggarwal A, Baker CS, Evans TW, et al. G-CSF and IL-8 but not GM-CSF correlate 
with severity of pulmonary neutrophilia in acute respiratory distress syndrome. Eur 
Respir J 2000; 15: 895-901. 
114  Leitch AE, Lucas CD, Rossi AG. Editorial: Neutrophil apoptosis: hot on the TRAIL of 
inflammatory resolution. J Leukoc Biol 2011; 90: 841-843. 
115  McGrath EE, Marriott HM, Lawrie A, et al. TNF-related apoptosis-inducing ligand 
(TRAIL) regulates inflammatory neutrophil apoptosis and enhances resolution of 
inflammation. J Leukoc Biol 2011; 90: 855-865. 
116  Hoodless LJ, Lucas CD, Duffin R, et al. Genetic and pharmacological inhibition of 
CDK9 drives neutrophil apoptosis to resolve inflammation in zebrafish in vivo. Sci Rep 
2016; 6: 36980. 
117  Leitch AE, Lucas CD, Marwick JA, et al. Cyclin-dependent kinases 7 and 9 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
specifically regulate neutrophil transcription and their inhibition drives apoptosis to 
promote resolution of inflammation. Cell Death Differ 2012; 19: 1950-1961. 
118  Witko-Sarsat V, Mocek J, Bouayad D, et al. Proliferating cell nuclear antigen acts as a 
cytoplasmic platform controlling human neutrophil survival. J Exp Med 2010; 207: 
2631-2645. 
119  Martin C, Ohayon D, Alkan M, et al. Neutrophil-expressed p21/waf1 favors 
inflammation resolution in Pseudomonas aeruginosa infection. Am J Respir Cell Mol 
Biol 2016; 54: 740-750. 
120  El Kebir D, Gjorstrup P, Filep JG. Resolvin E1 promotes phagocytosis-induced 
neutrophil apoptosis and accelerates resolution of pulmonary inflammation. Proc Natl 
Acad Sci U S A 2012; 109: 14983-14988. 
121  El Kebir D, József L, Pan W, et al. 15-epi-lipoxin A4 inhibits myeloperoxidase 
signaling and enhances resolution of acute lung injury. Am J Respir Crit Care Med 
2009; 180: 311-319. 
122  Hagimoto N, Kuwano K, Nomoto Y, et al. Apoptosis and expression of Fas/Fas ligand 
mRNA in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Cell Mol Biol 
1997; 16: 91-101. 
123  Guinee D, Brambilla E, Fleming M, et al. The potential role of BAX and BCL-2 
expression in diffuse alveolar damage. Am J Pathol 1997; 151: 999-1007. 
124  Matute-Bello G, Liles WC, Steinberg KP, et al. Soluble Fas ligand induces epithelial 
cell apoptosis in humans with acute lung injury (ARDS). J Immunol 1999; 163: 2217-
2225. 
125  Lopez AD, Avasarala S, Grewal S, et al. Differential role of the Fas/Fas ligand 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
apoptotic pathway in inflammation and lung fibrosis associated with reovirus 1/L-
induced bronchiolitis obliterans organizing pneumonia and acute respiratory distress 
syndrome. J Immunol 2009; 183: 8244-8257. 
126  Janssen WJ, Barthel L, Muldrow A, et al. Fas determines differential fates of resident 
and recruited macrophages during resolution of acute lung injury. Am J Respir Crit 
Care Med 2011; 184: 547-560. 
127  Cheng KT, Xiong S, Ye Z, et al. Caspase-11-mediated endothelial pyroptosis underlies 
endotoxemia-induced lung injury. J Clin Invest 2017; 127: 4124-4135. 
128  Kobori M, Yang Z, Gong D, et al. Wedelolactone suppresses LPS-induced caspase-11 
expression by directly inhibiting the IKK complex. Cell Death Differ 2004; 11: 123-
130. 
129  McCubbrey AL, Curtis JL. Efferocytosis and lung disease. Chest 2013; 143: 1750-
1757. 
130  Grégoire M, Uhel F, Lesouhaitier M, et al. Impaired efferocytosis and neutrophil 
extracellular trap clearance by macrophages in ARDS. Eur Respir J 2018; 52: 
1702590. 
131  Bae H-B, Zmijewski JW, Deshane JS, et al. AMP-activated protein kinase enhances 
the phagocytic ability of macrophages and neutrophils. FASEB J 2011; 25: 4358-4368. 
132  Jo YS, Choi SM, Lee J, et al. Effect of preadmission metformin use on clinical 
outcome of acute respiratory distress syndrome among critically ill patients with 
diabetes. Tuberc Respir Dis (Seoul) 2017; 80: 296-303. 
133  Ueno H, Matsuda T, Hashimoto S, et al. Contributions of high mobility group box 
protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
2004; 170: 1310-1316. 
134  Friggeri A, Yang Y, Banerjee S, et al. HMGB1 inhibits macrophage activity in 
efferocytosis through binding to the alphavbeta3-integrin. Am J Physiol Cell Physiol 
2010; 299: C1267-1276. 
135  Aziz M, Matsuda A, Yang W-L, et al. Milk fat globule-epidermal growth factor-factor 
8 attenuates neutrophil infiltration in acute lung injury via modulation of CXCR2. J 
Immunol 2012; 189: 393-402. 
136  Nourshargh S, Renshaw SA, Imhof BA. Reverse migration of neutrophils: where, 
when, how, and why? Trends Immunol 2016; 37: 273-286. 
137  Lucas CD, Hoodless LJ, Rossi AG. Swimming against the tide: drugs drive neutrophil 
reverse migration. Sci Transl Med 2014; 6: 225fs9-225fs9. 
138  Loynes CA, Lee JA, Robertson AL, et al. PGE2 production at sites of tissue injury 
promotes an anti-inflammatory neutrophil phenotype and determines the outcome of 
inflammation resolution in vivo. Sci Adv 2018; 4: eaar8320. 
139  Colom B, Bodkin J V, Beyrau M, et al. Leukotriene B4-neutrophil elastase axis drives 
neutrophil reverse transendothelial cell migration in vivo. Immunity 2015; 42: 1075-
1086. 
140  Famous KR, Delucchi K, Ware LB, et al. ARDS subphenotypes respond differently to 
randomized fluid management strategy. Am J Respir Crit Care Med 2017; 195: 331-
338. 
141  Calfee CS, Delucchi K, Parsons PE, et al. Subphenotypes in acute respiratory distress 
syndrome: latent class analysis of data from two randomised controlled trials. Lancet 
Respir Med 2014; 2: 611-620. 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
142  Ashbaugh DG, Bigelow DB, Petty TL, et al. Acute respiratory distress in adults. 
Lancet 1967; 2: 319-323. 
143  Fujishima S. Pathophysiology and biomarkers of acute respiratory distress syndrome. J 
Intensive Care 2014; 2: 32. 
144  Horiuchi T, Sakata N, Narumi Y, et al. Metformin directly binds the alarmin HMGB1 
and inhibits its proinflammatory activity. J Biol Chem 2017; 292: 8436-8446. 
145  Goodman RB, Strieter RM, Martin DP, et al. Inflammatory cytokines in patients with 
persistence of the acute respiratory distress syndrome. Am J Respir Crit Care Med 
1996; 154: 602-611. 
146  Zheng G, Huang L, Tong H, et al. Treatment of acute respiratory distress syndrome 
with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-
controlled pilot study. Respir Res 2014; 15: 39. 
147  Auner B, Geiger E V, Henrich D, et al. Circulating leukotriene B4 identifies 
respiratory complications after trauma. Mediators Inflamm 2012; 2012: 536156. 
148  Stephenson AH, Lonigro AJ, Hyers TM, et al. increased concentrations of leukotrienes 
in bronchoalveolar lavage fluid of patients with ARDS or at risk for ARDS. Am Rev 
Respir Dis 1988; 138: 714-719. 
149  Trujillo G, Zhang J, Habiel DM, et al. Cofactor regulation of C5a chemotactic activity 
in physiological fluids. Requirement for the vitamin D binding protein, 
thrombospondin-1 and its receptors. Mol Immunol 2011; 49: 495-503. 
150  Yang J, Azat M, Peng P, et al. Serum levels of TNF-α, IL-1β, IL-9, and IL-15 in acute 
respiratory distress syndrome. Int J Clin Exp Pathol 2017; 10: 781-788. 
151  Reutershan J, Ley K. Bench-to-bedside review: Acute respiratory distress syndrome – 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
how neutrophils migrate into the lung. Crit Care 2004; 8: 453-461. 
152  Kolaczkowska E, Jenne CN, Surewaard BGJ, et al. Molecular mechanisms of NET 
formation and degradation revealed by intravital imaging in the liver vasculature. Nat 
Commun 2015; 6: 6673. 
153  Idell S, Kucich U, Fein A, et al. Neutrophil elastase-releasing factors in 
bronchoalveolar lavage from patients with adult respiratory distress syndrome. Am Rev 
Respir Dis 1985; 132: 1098-1105. 
154  Wang Z, Chen F, Zhai R, et al. Plasma neutrophil elastase and elafin imbalance is 
associated with Acute Respiratory Distress Syndrome (ARDS) development. PLoS 
One 2009; 4: e4380. 
155  Mitra S, Schiller D, Anderson C, et al. Hypertonic saline attenuates the cytokine-
induced pro-inflammatory signature in primary human lung epithelia. PLoS One 2017; 
12: e0189536. 
156  Hästbacka J, Linko R, Tervahartiala T, et al. Serum MMP-8 and TIMP-1 in critically 
ill patients with acute respiratory failure. Anesth Analg 2014; 118: 790-798. 
157  Kietzmann D, Kahl R, Müller M, et al. Hydrogen peroxide in expired breath 
condensate of patients with acute respiratory failure and with ARDS. Intensive Care 
Med 1993; 19: 78-81. 
158  Perrella MA. A phase I trial of  inhaled carbon monoxide for the treatment of sepsis-
induced acute respiratory distress syndrome (ARDS). 
https://clinicaltrials.gov/ct2/show/NCT02425579 last updated July 2018. 
159  El Solh AA, Bhora M, Pineda L, et al. Alveolar plasminogen activator inhibitor-1 
predicts ARDS in aspiration pneumonitis. Intensive Care Med 2006; 32: 110-115. 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
 
Table 1. Neutrophil-related mediators in ARDS, pre-clinical observations and associated therapeutics 
  Pre-clinical observations Human ARDS Therapeutic potential Therapeutics Refs 
PAMPs Neutrophil recruitment and 
activation 
Unknown TLR1, TLR4, TLR5 
antagonists 
Not clinically tested [23,143] 
DAMPs Mitochondrial 
formylated 
peptides 
↑ neutrophil migration and 
inflammation 
↑ in blood and BALF FPR1 antagonists  Not clinically tested [31] 
 Mitochondrial 
DNA 
↑ neutrophil migration and 
inflammation 
↑ in blood and BALF TLR9 antagonists Not clinically tested [30] 
 HMGB1 ↑ neutrophils and inflammation ↑ in blood Metformin  No increase in survival [132,133,144] 
Chemokines 
/ Cytokines 
CXCL5 Neutrophil chemotaxis ↑ in BALF CXCL5 antibody 
CXCR2 antagonist 
Not clinically tested [145] 
 CXCL8 Neutrophil chemotaxis ↑ in blood and BALF CXCL8 antibody 
CXCR1, CXCR2 
antagonist 
allogeneic adipose-
derived mesenchymal 
stem cells – no effect 
[36,38,146] 
 CCL2 Neutrophil chemotaxis ↑ in BALF CCL2 antibody 
CCR2 antagonist 
Not clinically tested [39] 
 CCL7 Neutrophil chemotaxis ↑ in BALF CCL7 antibody 
CCR1, CCR2, CCR3 
antagonist 
Not clinically tested [39] 
 LTB4 Neutrophil chemotaxis ↑ in blood and BALF LTB4 antibody 
BLT2 antagonist 
Not clinically tested [147,148] 
 C5a Neutrophil chemotaxis ↑ in BALF Anti-DBP 
(DBP=Vitamin D binding 
protein) 
Not clinically tested [149] 
 TNF Pro-inflammatory response 
Microvascular plasma protein 
leakage 
↑ in blood and BALF TNF antibody 
TNF-RA 
Not clinically tested 
TNFR1 antibody - ↓ 
pulmonary neutrophilia, 
inflammatory cytokine 
release, endothelial 
injury 
[41,43,50,150] 
 IL-1β Pro-inflammatory response ↑ in blood and BALF IL-1β antibody Not clinically tested [50,150] 
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 IL-1RA  
 TNF receptor Neutralises TNF 
imbalance 
↑ in BALF Administration for TNF 
neutralisation 
Not clinically tested [50] 
 IL-1RA Neutralises IL-1β 
imbalance 
↑ in BALF Administration for IL-1β 
neutralisation 
Not clinically tested [50] 
Selectins L-selectin Aids in neutrophil migration Soluble form ↓ in blood  L-selectin antibody Not clinically tested [57,151] 
 E-selectin Aids in neutrophil migration Soluble form ↑ in blood E-selectin antibody Not clinically tested [57] 
 P-selectin Aids in neutrophil migration Soluble form ↑ in blood P-selectin antibody Not clinically tested [57,66] 
Integrins β2 integrin Aids in neutrophil migration ↑ sICAM-1in blood and 
BALF 
β2 integrin antibody Not clinically tested [62,65] 
NETs Lung injury ↑ in BALF DNAse I Inhaled DNAse I – 
Phase III 
[68,70,152] 
Granule 
proteins 
Neutrophil 
elastase 
Lung injury ↑ in blood and BALF Anti-elastase therapies No increase in survival [72,79,153,154] 
 Elafin Neutrophil elastase inhibitor ↓ in blood Administration Not clinically tested [154] 
 MMP-1 Lung injury ↑ in BALF Inhibit with TIMP Nebulised hypertonic 
saline- Phase I 
[83,86,88,155] 
 MMP-2 Lung injury ↑ in BALF Inhibit with TIMP Nebulised hypertonic 
saline- Phase I 
[83,86,88,155] 
 MMP-3 Lung injury ↑ in BALF Inhibit with TIMP Nebulised hypertonic 
saline- Phase I 
[83,86,88,155] 
 MMP-8 Lung injury ↑ in blood and BALF Inhibit with TIMP Nebulised hypertonic 
saline- Phase I 
[83,86,88,155,156] 
 MMP-9 Lung injury ↑ in BALF Inhibit with TIMP Nebulised hypertonic 
saline- Phase I 
[83,86,88,155] 
 TIMP-1 Inhibits MMPs ↑ in blood and BALF Administration Not clinically tested [83,156] 
 HBP Vascular leakage ↑ in blood Simvastatin reduced serum 
HBP  
Simvastatin ↑ survival 
in hyperinflammatory 
subphenotype 
[89,90,92,93] 
 α-defensin Lung injury ↑ in blood and BALF Inhibit Not clinically tested [95] 
 β-defensin Inhibit neutrophil apoptosis Unknown Inhibit Not clinically tested [96] 
 LL-37 Neutrophil activation ↑ in BALF Inhibit Not clinically tested [97] 
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Reactive 
oxygen 
species 
H2O2 Lung tissue damage 
Release pro-inflammatory 
mediators 
Immune cells recruitment 
↑ in breath condensate Neutralising with anti-
oxidants 
Pan-PI3K inhibitor 
Inhaled carbon 
monoxide – Phase I 
[99,112,157,158] 
 Glutathione Neutralises H2O2 ↑ oxidised glutathione in 
BALF 
Intravenous administration No effect [101,102] 
Apoptosis PAI-1 ↓ neutrophil apoptosis ↑ in BALF PAI-1 antagonist Not clinically tested [159] 
 Mcl-1 ↓ neutrophil apoptosis ↑ in ARDS neutrophils CDK inhibitor Not clinically tested [111] 
 
H2O2, Hydrogen peroxide; CCL/CXCL, chemokine ligands; PI3K, Phosphoinositide 3-kinase; BALF, bronchoalveolar lavage fluid; CXCR, chemokine receptor; LTB4, 
leukotriene B4; BLT2, leukotriene B4 receptor 2; DBP, Vitamin D binding protein; TNF, tumour necrosis factor; IL, interleukin; MMP, matrix metalloproteinase; TIMP, 
tissue inhibitors of metalloproteinases; HBP, heparin- binding protein; FPR, formyl peptide receptor; HMGB1, high mobility group box; TLR, toll-like receptor; PAI, 
Plasminogen activator inhibitor; CDK, cyclin dependent kinase. 
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Figure legends 
Figure 1. Initiation and resolution of neutrophil-mediated inflammation in ARDS.  (A) 
The healthy alveolar unit facilitates rapid gas transfer with the presence of resident alveolar 
macrophages providing rapid response to pulmonary infection and injury. (B) Following 
infection and/or tissue injury, release of pathogen associated molecular patterns (PAMPs) 
and/or damage associated molecular patterns (DAMPs) directly induces neutrophil 
recruitment into the alveolar space in addition to a range of chemokines and mediators 
secreted by macrophages and epithelial cells. (C) Neutrophils exert multiple pro-
inflammatory functions with the release of reactive oxygen species, proteases, neutrophil 
extracellular traps and cytokines as well as phagocytosis of bacteria. This is accompanied by 
accumulation of oedema within the alveolus, endothelial dysfunction and epithelial cell 
death. (D) Resolution of inflammation occurs through neutrophil apoptosis and macrophage 
clearance of apoptotic cells (efferocytosis) and inflammatory debris. The role of neutrophil 
reverse migration remains to be fully characterised in ARDS. 
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